Eribulin - Breast Cancer Drug That Could Extend Lives of Breast Cancer Patients Approved

Highlights

Breast cancer, the most common cancer in women
18.2% breast cancer deaths reported worldwide
Eribulin, life-extending drug for women with aggressive breast cancer

Women with breast cancer will now be able to benefit from Eribulin drug after the National Institute for Health and Care Excellence (NICE) agreed it should be made available across the NHS in England.

Eribulin received a European safety license more than five years ago, yet NICE has until now refused to make it routinely available on NHS. NICE has been criticized for sticking to a rigid formula for deciding whether the drug is cost-effective.

Breast Cancer - Prevention and Management with Lifestyle Changes
Lifestyle choices may or may not cause breast cancer but healthy lifestyle changes can open up avenues beyond breast cancer. Good habits will allow one to fight breast cancer and to live with dignity.

‘Eribulin (halaven) approved by UK regulators offers women with metastatic breast cancer three months of additional life compared to other therapies.’

Tweet it Now

Updated draft guidance from NICE states that the drug should be made available to women who have locally advanced or metastatic breast cancer that has spread after two rounds of chemotherapy. The drug is given intravenously twice every 3 weeks.

The medication had previously been only available through the Cancer Drugs Fund.

Women with advanced breast cancer are expected to live only two years on average, a drug giving extra three months of life is considered valuable.

Breast Cancer during Pregnancy - Staging, Signs, Diagnosis and Treatment
Management of breast cancer during pregnancy or pregnancy associated breast cancer requires special consideration to avoid harm to the fetus.

Working of Eribulin:

Eribulin, the chemotherapy drug works by stopping the cancer cells from spreading into new cancer cells and blocks the cancer growth. Common side effects associated with Eribulin include

Increased risk of getting infection
Tiredness and breathlessness
Fatigue
Hair thinning
Numbness

Breast Cancer Now chief executive Baroness Delyth Morgan said the drug will offer a "crucial" alternative to patients and its approval is positive news.

Quiz on Breast Cancer
Breast cancer is one of the leading causes of cancer deaths among women. It is often said that a woman who breast-feeds is at a lower risk of developing cancer compared to another who does not .Are these mere old wives tales or is there some truth in it? This quiz on breast cancer has all the details.

"It offers a crucial life-extending alternative for patients whose breast cancer has become resistant to other therapies, and for those with triple negative disease, who desperately lack treatment options," she said.

Professor Carole Longson, director of the centre for health technology evaluation at Nice, said: “The life expectancy of people for whom eribulin is licensed is short, and quality of life is very important.”

Young Female Alcoholics at Risk of Breast Cancer
Those who regularly consume alcohol from the age of 15 till their first pregnancy have 35 percent higher risk of developing breast cancer.

She said: “But the real tests are still yet to come and we now eagerly await Nice’s decision on the even more effective drugs being appraised, including Kadcyla.

NICE is currently reviewing all drugs funded to see whether they meet its strict cost-effectiveness thresholds.

Eribulin is one of the first to be moved from the temporary Cancer Drugs Fund use to routine NICE approval.

Reference

Eribulin - General Information - (http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/eribulin/)

Source-Medindia